Aptevo Therapeutics Inc.
APVO
$8.81
-$0.17-1.89%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -274.00K | -274.00K | -274.00K | -103.00K | -323.00K |
| Gross Profit | 274.00K | 274.00K | 274.00K | 103.00K | 323.00K |
| SG&A Expenses | 11.81M | 10.36M | 9.84M | 10.22M | 10.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.70M | 24.30M | 24.10M | 24.60M | 24.60M |
| Operating Income | -26.70M | -24.30M | -24.10M | -24.60M | -24.60M |
| Income Before Tax | -26.47M | -24.03M | -23.70M | -24.13M | -24.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.47 | -24.03 | -23.70 | -24.13 | -24.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 293.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.47M | -24.03M | -23.70M | -24.13M | -23.72M |
| EBIT | -26.70M | -24.30M | -24.10M | -24.60M | -24.60M |
| EBITDA | -26.47M | -24.04M | -23.79M | -24.25M | -24.21M |
| EPS Basic | -191.42 | -151.29 | -- | -- | -- |
| Normalized Basic EPS | -115.53 | -94.55 | -- | -- | -- |
| EPS Diluted | -191.42 | -151.29 | -- | -- | -- |
| Normalized Diluted EPS | -115.53 | -94.55 | -- | -- | -- |
| Average Basic Shares Outstanding | 265.90K | 41.00K | -- | -- | -- |
| Average Diluted Shares Outstanding | 265.90K | 41.00K | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |